UCB

UCB.VIApproved

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

Market Cap

$54.2B

Employees

8,000-9,000

Focus

Biotech

UCB.VI · Stock Price

USD 247.00+132.60 (+115.91%)

Historical price data

AI Company Overview

Technology Platform

Specialized biopharmaceutical platform focusing on neuroscience and immunology with expertise in antibody engineering, CNS drug development, and translational medicine for severe neurological and inflammatory diseases.

Pipeline Snapshot

609

609 drugs in pipeline, 261 in Phase 3

Drug	Indication	Stage
Levetiracetam	Epilepsy, Partial	Approved
Rozanolixizumab	Myasthenia Gravis	Approved
Levetiracetam	Epilepsy	Approved
Levocetirizine + Placebo	Allergic Rhinitis	Approved
Levetiracetam + Clonidine	Tic Disorders	Approved

Funding History

Total raised: $1.2B

Debt$1.2BUndisclosedMay 15, 2020

FDA Approved Drugs

KYGEVVINDANov 3, 2025

ZILBRYSQNDAOct 17, 2023

BIMZELXBLAOct 17, 2023

Opportunities

UCB has significant growth opportunities through its pipeline expansion in rare neurological disorders and successful commercialization of bimekizumab across multiple inflammatory indications.

The company's focused strategy in high-value therapeutic areas with unmet medical needs positions it well for premium pricing and market leadership.

Risk Factors

Key risks include patent expirations on major revenue drivers like Keppra, clinical development risks in complex neurological indications, and intense competitive pressure in immunology markets.

Regulatory challenges for CNS drugs and pricing pressures from payers also present ongoing challenges.

Competitive Landscape

UCB competes with major pharmaceutical companies including Novartis, AbbVie, and Johnson & Johnson across its neurology and immunology franchises. The company differentiates through its specialized focus, strong R&D capabilities in CNS disorders, and patient-centric approach in niche therapeutic areas with high unmet medical needs.

Publications

Patents

Pipeline

609

FDA Approvals